ACCPL

Accretion Pharmaceuticals Share Price

 

 

Start SIP in ACCPL

Start SIP

Performance

  • Low
  • ₹77
  • High
  • ₹79
  • 52 Week Low
  • ₹54
  • 52 Week High
  • ₹103
  • Open Price₹79
  • Previous Close₹77
  • Volume6,000
  • 50 DMA₹81.07
  • 100 DMA₹75.80
  • 200 DMA-

Investment Returns

  • Over 1 Month -20.42%
  • Over 3 Month + 31.77%
  • Over 6 Month + 17.91%
  • Over 1 Year -23.42%

Smart Investing Starts Here Start SIP with Accretion Pharmaceuticals for Steady Growth!

Invest Now

Accretion Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 86
  • P/B Ratio
  • 1.8
  • Average True Range
  • 4.12
  • EPS
  • 6.11
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.78
  • RSI
  • 38.08
  • MFI
  • 27.73

Accretion Pharmaceuticals Financials

Accretion Pharmaceuticals Technicals

EMA & SMA

Current Price
₹77.35
+ 0.25 (0.32%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 3
  • 20 Day
  • ₹84.68
  • 50 Day
  • ₹81.07
  • 100 Day
  • ₹75.80
  • 200 Day
  • -

Resistance and Support

78.05 Pivot Speed
  • R3 80.85
  • R2 80.15
  • R1 78.75
  • S1 76.65
  • S2 75.95
  • S3 74.55

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Accretion Pharmaceuticals Limited manufactures high-quality pharmaceutical and nutraceutical products using advanced technology. With a state-of-the-art facility and over 200 professionals, it serves global markets by delivering affordable, effective healthcare solutions to improve lives and build healthier communities.

Accretion Pharmaceuticals Ltd has an operating revenue of Rs. 136.78 Cr. on a trailing 12-month basis. An annual revenue growth of 69% is outstanding, Pre-tax margin of 17% is great, ROE of 44% is exceptional. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 11% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart and is trading around -7% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 91 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Accretion Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-06-10 Audited Results & Others To consider Other business matters.

Accretion Pharmaceuticals F&O

Accretion Pharmaceuticals Shareholding Pattern

73.52%
1.16%
22.86%
2.46%

About Accretion Pharmaceuticals

  • NSE Symbol
  • ACCPL
  • BSE Symbol
  • Managing Director
  • Mr. Vivek Ashok Kumar Patel
  • ISIN
  • INE0T8T01010

Similar Stocks to Accretion Pharmaceuticals

Accretion Pharmaceuticals FAQs

Accretion Pharmaceuticals share price is ₹77 As on 12 January, 2026 | 04:00

The Market Cap of Accretion Pharmaceuticals is ₹86 Cr As on 12 January, 2026 | 04:00

The P/E ratio of Accretion Pharmaceuticals is 12.7 As on 12 January, 2026 | 04:00

The PB ratio of Accretion Pharmaceuticals is 1.8 As on 12 January, 2026 | 04:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23